SA
BIIB icon

Steadfast Advisors’s Biogen BIIB Stock Holding History

Steadfast Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,045
Closed -$2.16M – 58
2015
Q4 		$2.16M Sell
7,045
-33,093
-82% -$9.51M 1% 32
2015
Q3 		$11.7M Buy
+40,138
New +$13.3M 5.56% 3

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Steadfast Advisors's BIIB Position: Q1 2016 in Review

Steadfast Advisors sold out of Biogen (BIIB) in Q1 2016, closing a stake of 7,045 shares — an estimated $2.16M sold.

Steadfast Advisors first reported a position in BIIB in Q3 2015 and held it in 2 quarters. The position peaked at $11.7M in Q3 2015. 948 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

  • Steadfast Advisors reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
  • Steadfast Advisors sold 7,045 Biogen shares in Q1 2016, an estimated $2.16M.
  • Steadfast Advisors first reported a position in Biogen in Q3 2015 and held it in 2 quarters.
  • Steadfast Advisors's Biogen position peaked at $11.7M in Q3 2015.
  • 948 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Steadfast Advisors's 13F filing for Q1 2016, filed 16 May 2016.